Deciphera Pharmaceuticals (NASDAQ:DCPH) Reaches New 12-Month High at $17.73

Deciphera Pharmaceuticals (NASDAQ: DCPH) has recently reached a new 12-month high of $17.73 per share. This represents an increase of approximately 40% from its previous 52-week low of $12.89, which was recorded on August 16, 2021.

Deciphera Pharmaceuticals is a biopharmaceutical company that focuses on the development and commercialization of novel therapies for rare genetic diseases. The company's lead product, Cabalegron, is an FDA-approved treatment for patients with pulmonary arterial hypertension (PAH), a serious condition characterized by high blood pressure in the arteries that supply blood to the lungs.

In addition to Cabalegron, Deciphera Pharmaceuticals has several other products in development, including a potential treatment for idiopathic pulmonary fibrosis (IPF) and a potential treatment for patients with PAH who are unable to tolerate or are not candidates for other available therapies.

Deciphera Pharmaceuticals' stock performance has been strong in recent months, driven by positive news about its products and the overall growth of the biopharmaceutical industry. The company's recent 12-month high is a reflection of this positive sentiment and investor confidence in the company's ability to continue delivering value for its shareholders.